EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Validation of claims‐based algorithms for rheumatoid arthritis in Japan: Results from the VALIDATE‐J study

Naonobu Sugiyama iD, Mitsuyo Kinjo, Sadao Jinno, Cynthia de Luise, Toshitaka Morishima, Takakazu Higuchi, Kayoko Katayama, Haoqian Chen, Edward Nonnenmacher, Ryota Hase, Daisuke Suzuki, Yoshiya Tanaka iD und 1 weitere

International Journal of Rheumatic Diseases · 2024

DOI: 10.1111/1756-185x.15001 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von Naonobu Sugiyama und 12 weiteren Autor:innen. Beteiligte Einrichtung: Inflammation and Immunology, Medical Affairs, Pfizer Japan, Tokyo, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Psoriasis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Validity of Algorithms in Large Databases: Infectious Diseases, Rheumatoid Arthritis, and Tumor Evaluation in Japan (VALIDATE‐J) study examined algorithms for identifying rheumatoid arthritis (RA) in Japanese claims data.

Methods

VALIDATE‐J was a multicenter, cross‐sectional retrospective study. Disease‐identifying algorithms were used to detect RA diagnosed between January 2012 and December 2016 using claims data from two Japanese hospitals. An RA diagnosis was confirmed using one of four gold standard definitions. Positive predictive values (PPVs) were calculated for prevalent (regardless of baseline RA‐free period) and incident (preceded by a 12‐month RA‐free period) cases.

Results

Of patients identified using claims‐based algorithms, a random sample of 389 prevalent and 134 incident cases of RA were included. Cases identified by an RA diagnosis, no diagnosis of psoriasis, and treatment with any disease‐modifying antirheumatic drugs (DMARDs) resulted in the highest PPVs versus other claims‐based treatment categories (29.0%–88.3% [prevalent] and 41.0%–78.2% [incident]); cases identified by an RA diagnosis, no diagnosis of psoriasis, and glucocorticoid‐only treatment had the lowest PPVs. Across claims‐based algorithms, PPVs were highest when a physician diagnosis or decision by adjudicators (confirmed and probable cases) was used as the gold standard and were lowest when American College of Rheumatology/European Alliance of Associations for Rheumatology 2010 criteria were applied. PPVs of claims‐based algorithms for RA in patients aged ≥66 years were slightly higher versus a USA Medicare population (maximum PPVs of 95.0% and 88.9%, respectively).

Conclusion

VALIDATE‐J demonstrated high PPVs for most claims‐based algorithms for diagnosis of prevalent and incident RA using Japanese claims data. These findings will help inform appropriate RA definitions for future claims database research in Japan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsPsoriasisHumansUnited StatesJapanRetrospective StudiesCross-Sectional StudiesAlgorithmsDatabases, Factual

Stichwörter der Autor:innen

Japanclaims-based algorithmpositive predictive valuerheumatoid arthritisvalidation

Substanzen

Antirheumatic Agents

Autor:innen und Institutionen

  • Inflammation and Immunology, Medical Affairs, Pfizer Japan, Tokyo, Japan.
  • Division of Rheumatology, Okinawa Chubu Hospital, Uruma, Okinawa, Japan.
  • Section of Rheumatology, Kobe University School of Medicine, Kobe, Hyogo, Japan.
  • Safety Surveillance Research, Pfizer Inc, New York, New York, USA.
  • Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
  • Blood Transfusion Department, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan.

ORCID-Profile: Naonobu Sugiyama, Yoshiya Tanaka

Förderung

  • Pfizer

Zitieren

APA

Sugiyama, N., Kinjo, M., Jinno, S., de Luise, C., Morishima, T., Higuchi, T., Katayama, K., Chen, H., Nonnenmacher, E., Hase, R., Suzuki, D., Tanaka, Y., & Setoguchi, S. (2024). Validation of claims‐based algorithms for rheumatoid arthritis in Japan: Results from the VALIDATE‐J study. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.15001

Vancouver

Sugiyama N, Kinjo M, Jinno S, de Luise C, Morishima T, Higuchi T, et al. Validation of claims‐based algorithms for rheumatoid arthritis in Japan: Results from the VALIDATE‐J study. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.15001

BibTeX
@article{Sugiyama2024,
  author = {Sugiyama, Naonobu and Kinjo, Mitsuyo and Jinno, Sadao and de Luise, Cynthia and Morishima, Toshitaka and Higuchi, Takakazu and Katayama, Kayoko and Chen, Haoqian and Nonnenmacher, Edward and Hase, Ryota and Suzuki, Daisuke and Tanaka, Yoshiya and Setoguchi, Soko},
  title = {Validation of claims‐based algorithms for rheumatoid arthritis in Japan: Results from the VALIDATE‐J study},
  journal = {International Journal of Rheumatic Diseases},
  year = {2024},
  doi = {10.1111/1756-185x.15001}
}
Kostenlos starten →